# Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

> **NCT04371939** · PHASE2 · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 30 (estimated)

## Conditions studied

- Wiskott-Aldrich Syndrome

## Interventions

- **DRUG:** Romiplostim
- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT04371939
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-05
- **Primary completion:** 2022-12
- **Final completion:** 2023-07-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371939, "Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT04371939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*